New allergy shot for teens enters early safety testing

This early-stage study is checking the safety and how the body processes a new injection called LP-003 in teenagers aged 12 to 18 who have allergic diseases like asthma, eczema, or hay fever. It's a small, open-label trial at one center, meaning everyone gets the drug and researchers watch closely for side effects. The main goal is to see how safe it is and how long it stays in the bloodstream, while also measuring its effect on allergy-related proteins.